High real-world efficacy of elbasvir/grazoprevir (EBR/GZR) in genotype 1 (GT1) infected patients with and without liver cirrhosis: results from the German Hepatitis C Registry (DHC-R)

In the past, HCV treatment was less successful in patients (pts) with liver cirrhosis. In pts with GT1 and GT4 infection EBR/GZR has demonstrated high efficacy across clinical studies. Information about the real-world efficacy of EBR/GZR in pts with liver cirrhosis is still scarce. Therefore, we investigated the real-world utilization and effectiveness of EBR/GZR treatment regimens in pts with and without cirrhosis in a large GT1 cohort of the German Hepatitis C Registry.